Featured Press Releases

Shorla Oncology Announces the Launch of Dedicated Sales Force and Market Access Teams as Part of Expansion of Its U.S. Commercial Footprint

Shorla Oncology Announces the Launch of Dedicated Sales Force and Market Access Teams as Part of Expansion of Its U.S. Commercial Footprint

AI Utilized by TNF Pharmaceuticals and Renova Health to Accelerate Drug Development

AI Utilized by TNF Pharmaceuticals and Renova Health to Accelerate Drug Development

  • 22 Apr 2025

TNF Pharmaceuticals, Inc. a clinical stage biopharmaceutical company committed to developing novel...

Regemat 3D to Distribute VitroInk® Bioinks in Europe: A Strategic Move for Advanced Bioprinting Solutions

Regemat 3D to Distribute VitroInk® Bioinks in Europe: A Strategic Move for Advanced Bioprinting Solutions

nuBioAge, nuHx, and Marius Pharmaceuticals launch a collaborative GLP-1 comparison study in male patients.

nuBioAge, nuHx, and Marius Pharmaceuticals launch a collaborative GLP-1 comparison study in male patients.

T3D Therapeutics to present Phase 2 results of T3D-959 for reducing Alzheimer

T3D Therapeutics to present Phase 2 results of T3D-959 for reducing Alzheimer's amyloid plaques

Nona Biosciences Updates on ADC Collaboration with BeiGene and DualityBio

Nona Biosciences Updates on ADC Collaboration with BeiGene and DualityBio

FDA Approves New 2-Gram Fibryga® Presentation to Improve Convenience and Precision in Treating Acquired Fibrinogen Deficiency

FDA Approves New 2-Gram Fibryga® Presentation to Improve Convenience and Precision in Treating Acquired Fibrinogen Deficiency

  • Octapharma
  • 08 Jan 2026
Ark Biopharmaceutical Granted China Marketing Authorization for Aizhida in ADHD Treatment

Ark Biopharmaceutical Granted China Marketing Authorization for Aizhida in ADHD Treatment

  • Arkbio
  • 08 Jan 2026
Novotech Appoints Anand Tharmaratnam as Chief Executive Officer

Novotech Appoints Anand Tharmaratnam as Chief Executive Officer

  • Novotech
  • 08 Jan 2026
Coya Therapeutics Announces Results from an Investigator-Initiated Study Showing Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients Treated with Low-Dose IL-2 and CTLA4-Ig

Coya Therapeutics Announces Results from an Investigator-Initiated Study Showing Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients Treated with Low-Dose IL-2 and CTLA4-Ig

  • Coya Therapeutics, Inc.
  • 08 Jan 2026
RoslinCT and BOOST Pharma Form Strategic Manufacturing Partnership to Advance Cell Therapy for Osteogenesis Imperfecta

RoslinCT and BOOST Pharma Form Strategic Manufacturing Partnership to Advance Cell Therapy for Osteogenesis Imperfecta

  • RoslinCT and BOOST Pharma
  • 07 Jan 2026
Orum Therapeutics Names Chad May Chief Scientific Officer to Advance Degrader-Antibody Conjugate Programs

Orum Therapeutics Names Chad May Chief Scientific Officer to Advance Degrader-Antibody Conjugate Programs

  • Orum Therapeutics
  • 05 Jan 2026
Drug Discovery 2024
The Digital Pharma Advances Conference 2026

Most Popular
January   2026
M T W T F S S
      1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31  

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.